Technical Analysis for NERV - Minerva Neurosciences, Inc

Grade Last Price % Change Price Change
grade F 7.07 -0.98% -0.07
NERV closed down 0.98 percent on Friday, January 18, 2019, on 1.14 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NERV trend table...

Date Alert Name Type % Chg
Jan 18 20 DMA Support Bullish 0.00%
Jan 16 NR7 Range Contraction -1.94%
Jan 15 Overbought Stochastic Strength -0.98%
Jan 15 Down 3 Days in a Row Weakness -0.98%
Jan 14 Weak + Overbought Other -3.15%
Jan 14 Overbought Stochastic Strength -3.15%
Jan 11 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.85%
Jan 11 Spinning Top Other -6.85%
Jan 11 NR7 Range Contraction -6.85%
Jan 11 Weak + Overbought Other -6.85%

Older signals for NERV ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Is NERV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.95
52 Week Low 5.0
Average Volume 151,832
200-Day Moving Average 8.6368
50-Day Moving Average 7.7452
20-Day Moving Average 6.938
10-Day Moving Average 7.315
Average True Range 0.4269
ADX 20.06
+DI 17.7237
-DI 20.003
Chandelier Exit (Long, 3 ATRs ) 6.4593
Chandelier Exit (Short, 3 ATRs ) 7.2707
Upper Bollinger Band 7.8281
Lower Bollinger Band 6.0479
Percent B (%b) 0.57
BandWidth 25.658691
MACD Line -0.1346
MACD Signal Line -0.218
MACD Histogram 0.0834
Fundamentals Value
Market Cap 300.54 Million
Num Shares 42.5 Million
EPS -1.08
Price-to-Earnings (P/E) Ratio -6.55
Price-to-Sales 0.00
Price-to-Book 2.36
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.48
Resistance 3 (R3) 7.47 7.32 7.41
Resistance 2 (R2) 7.32 7.22 7.33 7.38
Resistance 1 (R1) 7.20 7.16 7.13 7.21 7.36
Pivot Point 7.05 7.05 7.02 7.06 7.05
Support 1 (S1) 6.93 6.95 6.86 6.94 6.78
Support 2 (S2) 6.78 6.89 6.79 6.76
Support 3 (S3) 6.66 6.78 6.73
Support 4 (S4) 6.67